严氏温阳化瘀利水方治疗心力衰竭的临床研究
|
摘要
目的:观察严氏温阳化瘀利水方治疗心力衰竭的临床疗效。方法:将100例心力衰竭患者按随机数字表法分为对照组和观察组。对照组给予西医常规抗心力衰竭治疗,观察组在对照组基础上给予严氏温阳化瘀利水方,2组患者均以14 d为1个疗程,连续治疗2个疗程。评价两组患者的临床疗效,检测治疗前后血浆N末端脑钠肽前体(N-terminal pro-brain natriuretic peptide,NT-pro BNP)水平和左室射血分数(LVEF),并进行6 min步行试验。结果:观察组临床总有效率为88.0%,对照组为72.0%,观察组高于对照组(P<0.05);治疗后,2组患者血浆NT-pro BNP水平均较治疗前下降(P<0.05),观察组低于对照组(P<0.05);治疗后2组患者的LVEF均较治疗前升高(均P<0.05),观察组高于对照组(P<0.05);治疗后2组患者的6 min步行试验均较治疗前改善(均P<0.05),观察组优于对照组(P<0.05)。结论:严氏温阳化瘀利水方可以提高心力衰竭的疗效,能够降低NT-pro BNP水平,改善心功能。
Objective:To observe the curative effect of heart failure treated with Yanshi Wenyang Huayu Lishui Fang.Methods:100 cases with heart failure were divided into two groups randomly according to random number table,control group was treated with routine treatment of Western Medicine,observation group was given Yanshi Wenyang Huayu Lishui Fang on the basis of control group,14 days was one treatment course,they were treated for 2 courses.Curative effect was evaluated,plasm BNP level of the two groups was determined before and after treatment,LVEF and 6 min walking distance were detected,too.Results:The effective rate of observation group was 88.0%,that was higher than that of control group( 72.0%),the curative effect of observation group was better than that of control group( P < 0.05).The plasm BNP level of the two groups was decreased significantly after treatment( P < 0.05),plasm BNP level of observation group was lower than that of control group( P < 0.05).LVEF of the two groups was raised( P < 0.05),LVEF of the observation group was higher than that of control group( P < 0.05).6 min walking distance was increased in the two groups,that in observation group was more obvious than that of control group( P < 0.05).Conclusion:Yanshi Wenyang Huayu Lishui Fang can improve the curative effect of heart failure,lower plasm BNP level and enhance heart function.
Objective:To observe the curative effect of heart failure treated with Yanshi Wenyang Huayu Lishui Fang.Methods:100 cases with heart failure were divided into two groups randomly according to random number table,control group was treated with routine treatment of Western Medicine,observation group was given Yanshi Wenyang Huayu Lishui Fang on the basis of control group,14 days was one treatment course,they were treated for 2 courses.Curative effect was evaluated,plasm BNP level of the two groups was determined before and after treatment,LVEF and 6 min walking distance were detected,too.Results:The effective rate of observation group was 88.0%,that was higher than that of control group( 72.0%),the curative effect of observation group was better than that of control group( P < 0.05).The plasm BNP level of the two groups was decreased significantly after treatment( P < 0.05),plasm BNP level of observation group was lower than that of control group( P < 0.05).LVEF of the two groups was raised( P < 0.05),LVEF of the observation group was higher than that of control group( P < 0.05).6 min walking distance was increased in the two groups,that in observation group was more obvious than that of control group( P < 0.05).Conclusion:Yanshi Wenyang Huayu Lishui Fang can improve the curative effect of heart failure,lower plasm BNP level and enhance heart function.
引文
[1]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2016》概要[J].中国循环杂志,2017,32(6):521
[2]Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC).Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur J Heart Fail,2016,18(8):891-975.
[3]Jiang H,Ge J.Epidemiology and clinical management of cardiomyopathies and heart failure in China[J].Heart,2009,95(21):1727-1731.
[4]Taylor A J,Villines T C,Stanek E J.Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe[J].Eur Heart J,2012,33(23):2939-2945.
[5]Mao J,Hou Y,Shang H,et al.Study on the evaluation of the clinical effects of traditional Chinese medicine in heart failure by complex intervention:protocol of SECETCMHF[J].Trials,2009,24(10):122.
[6]郭美珠,黄国毅,严骅.严世芸教授治疗慢性心力衰竭用药聚类分析[J].中西医结合心脑血管病杂志,2016,14(22):2710-2713.
[7]马文欢,陈丽云,郭美珠,等.严世芸教授治疗慢性心力衰竭阳虚水泛证中药数据挖据分析[J].中华中医药学刊,2016,1(1):214-217.
[8]Jessup M,Abraham WT,Casey DE,et al.2009 focusDD update incorporat DD into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults[J].J Am Coll Cardiol,2009,53(15):e1-e90.
[9]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:77-85.
[10]张子彬,Tsung O.Cheng(美),张玉传.充血性心力衰竭学[M].北京:科学技术文献出版社,2002:567-568.
[11]蔡虎志,陈青扬,陈新宇.重用附子治疗慢性心力衰竭的理论探讨[J].湖南中医杂志,2015,31(12):132-133.
[12]陈荣昌,孙桂波,张强,等.附子及其复方中药的药理作用研究进展[J].中草药,2014,45(6):883-888.
[13]邢文龙,刘红旭.参附注射液治疗慢性心力衰竭药理机制研究进展[J].北京中医药,2014,33(9):716-719.
[14]胡彦武,刘凯,闫梦彤,等.淫羊藿总黄酮及淫羊藿苷的心血管保护作用及机制研究进展[J].中国实验方剂学杂志,2015,21(13):227-230.
[15]刘洋,华树东,贺永贵,等.黄芪对心房收缩力及心房钠尿肽分泌的影响[J].中国中药杂志,2008,33(19):2226-2229.
[2]Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC).Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur J Heart Fail,2016,18(8):891-975.
[3]Jiang H,Ge J.Epidemiology and clinical management of cardiomyopathies and heart failure in China[J].Heart,2009,95(21):1727-1731.
[4]Taylor A J,Villines T C,Stanek E J.Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe[J].Eur Heart J,2012,33(23):2939-2945.
[5]Mao J,Hou Y,Shang H,et al.Study on the evaluation of the clinical effects of traditional Chinese medicine in heart failure by complex intervention:protocol of SECETCMHF[J].Trials,2009,24(10):122.
[6]郭美珠,黄国毅,严骅.严世芸教授治疗慢性心力衰竭用药聚类分析[J].中西医结合心脑血管病杂志,2016,14(22):2710-2713.
[7]马文欢,陈丽云,郭美珠,等.严世芸教授治疗慢性心力衰竭阳虚水泛证中药数据挖据分析[J].中华中医药学刊,2016,1(1):214-217.
[8]Jessup M,Abraham WT,Casey DE,et al.2009 focusDD update incorporat DD into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults[J].J Am Coll Cardiol,2009,53(15):e1-e90.
[9]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:77-85.
[10]张子彬,Tsung O.Cheng(美),张玉传.充血性心力衰竭学[M].北京:科学技术文献出版社,2002:567-568.
[11]蔡虎志,陈青扬,陈新宇.重用附子治疗慢性心力衰竭的理论探讨[J].湖南中医杂志,2015,31(12):132-133.
[12]陈荣昌,孙桂波,张强,等.附子及其复方中药的药理作用研究进展[J].中草药,2014,45(6):883-888.
[13]邢文龙,刘红旭.参附注射液治疗慢性心力衰竭药理机制研究进展[J].北京中医药,2014,33(9):716-719.
[14]胡彦武,刘凯,闫梦彤,等.淫羊藿总黄酮及淫羊藿苷的心血管保护作用及机制研究进展[J].中国实验方剂学杂志,2015,21(13):227-230.
[15]刘洋,华树东,贺永贵,等.黄芪对心房收缩力及心房钠尿肽分泌的影响[J].中国中药杂志,2008,33(19):2226-2229.